9 / 18
Prior endocrine therapy status criteria
9
First line
(i.e. treatment-naive for ABC)
Second line + early relapsers
(i.e. received up to 1 line of prior endocrine therapy for ABC)
•
Relapse
>12 months after completion of
(neo)adjuvant endocrine therapy
OR
•
De novo
advanced/metastatic disease
(no prior exposure to endocrine
therapy)
•
Early relapse
on or ≤12 months from
completion of (neo)adjuvant endocrine
therapy
OR
•
Relapse
>12 months from completion of
(neo)adjuvant endocrine therapy with
subsequent
progression
after 1 line of
endocrine therapy (antiestrogen/AI) for ABC
OR
•
ABC at diagnosis that
progressed
after
1 line of endocrine therapy (antiestrogen/AI)
for ABC